Nanovibronix Inc Stock Price, News & Analysis

NanoVibronix Inc. (NASDAQ: NAOV), a medical device company, will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. CEO Brian Murphy will discuss the company's business and products, including the UroShield® and PainShield® devices, which utilize surface acoustic wave technology for therapeutic applications. The presentation will be available online starting on January 10 at 7 AM ET, with a recording accessible for 90 days. For registration, visit the conference link.

NanoVibronix Inc (NASDAQ: NAOV) has partnered with Delta Medical to distribute its PainShield devices to Veterans Administration (VA) facilities. This collaboration, facilitated by Applied Medical Solutions, aims to enhance sales of PainShield products across over 1700 targeted VA locations. Delta Medical, led by veteran Justin A. Brooks, has a unique focus on non-opioid treatments for chronic pain management. PainShield aims to address veterans’ pain effectively while minimizing risks associated with opioid use.

NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company, has signed a two-year agreement with Applied Medical Solutions to distribute its PainShield products to Veterans Administration facilities across the U.S. CEO Brian Murphy highlighted the opportunity to serve nine million veterans annually, emphasizing the growing demand for non-opioid pain management solutions. Initial sales indicate strong adoption within select VA facilities, which could positively impact revenue in the upcoming quarters. PainShield is an ultrasound device designed for pain treatment and soft tissue healing, enabling patient use at home or work.

NanoVibronix, Inc. (NASDAQ: NAOV) announced that its Special Meeting of Stockholders, initially set for December 21, 2021, has been adjourned due to a lack of quorum and will reconvene on December 29, 2021. During this period, the company will solicit proxies from stockholders regarding proposals in the proxy statement. Stockholders can vote online or by phone until December 28, 2021. NanoVibronix specializes in noninvasive medical devices targeting wound healing and pain therapy using ultrasound technology.

NanoVibronix Inc. (NASDAQ: NAOV) has announced the commencement of sales in Europe following a distribution agreement with Medina Healthcare Ltd in Malta. This partnership aims to leverage Medina's distribution capabilities to penetrate the European market. The company has regulatory approval to sell its products, including UroShield and PainShield, which address healthcare needs such as preventing infections and managing chronic pain. The initial order from Medina signifies confidence in NanoVibronix's technology and market potential.

NanoVibronix, a healthcare device company, is set to showcase its PainShield products at the Workers’ Compensation Institute’s 75th Annual Conference, happening from December 12-15, 2021 in Orlando, Florida. CEO Brian Murphy highlighted the significant opportunity in the workers' compensation market, emphasizing a new agreement that facilitates reimbursement for their devices. PainShield utilizes safe ultrasound technology for pain management and is designed for various settings, promoting ease of use and fast recovery.

NanoVibronix (NASDAQ: NAOV) announced positive interim results from an independent study on its UroShield device, highlighting a significant 1 log reduction in bacterial counts among patients. Conducted at Southampton University, the study aims to assess UroShield's effectiveness in preventing infections related to urinary catheters. Patients reported improved quality of life with the device. Southern Health is set to purchase UroShield for ongoing use after the study concludes in Q2 2022. The company emphasized the strong interest from clinical teams and patients during the study.

NanoVibronix, Inc. (NASDAQ: NAOV), a healthcare device company, reported accelerating sales of its PainShield device to the Veterans Administration (VA). CEO Brian Murphy noted that adoption is increasing, with higher reorders of accompanying disposables, indicating high patient satisfaction. The VA's commitment to non-opioid pain management creates significant growth opportunities for NanoVibronix, as it seeks to expand production capacity to meet rising demand. PainShield offers localized ultrasound therapy for various pain conditions, emphasizing compliance and safety over traditional methods.

NanoVibronix, Inc. (NASDAQ: NAOV) reported significant growth in its third quarter 2021, with revenues of $499,000, a 233% increase year-over-year. The company introduced a new CBD gel for pain management and expanded into the workers' compensation market. A backlog of orders exceeds $600,000, indicating strong sales momentum. Despite a net loss of $6.7 million, the balance sheet remains robust with $8.6 million in cash and no long-term debt. Future catalysts include new product launches and expanding markets.